Price
Target price
€53.00
€53.00
1.020%
0.54
1.020%
€67.75
12.12.25 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
There is an upward development for Halozyme Therapeutics Inc. compared to yesterday, with an increase of €0.54 (1.020%).
With 21 Buy predictions and 2 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 67 € there is a positive potential of 26.42% for Halozyme Therapeutics Inc. compared to the current price of 53.0 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 1.020% | -2.574% | -13.058% | 15.923% | 15.974% | -3.811% | 56.388% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -14.490% | -75.357% | -72.809% | -71.362% | -95.447% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $56.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for HALO provided by MarketBeat
News
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look
On November 5, 2025, Renaissance Group LLC initiated a new position in Halozyme Therapeutics (NASDAQ:HALO), acquiring 478,735 shares for an estimated $35.11 million, according to a recent SEC
Halozyme (HALO) Q2 EPS Jumps 69%
Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is